Seres Therapeutics Inc. (MCRB) Stock Price Up 4%
Seres Therapeutics Inc. (NASDAQ:MCRB)’s share price rose 4% during mid-day trading on Monday . The stock traded as high as $10.08 and last traded at $9.98, with a volume of 597,149 shares changing hands. The stock had previously closed at $9.60.
MCRB has been the subject of several recent research reports. HC Wainwright initiated coverage on shares of Seres Therapeutics in a report on Friday, July 29th. They set a “buy” rating and a $50.00 target price for the company. Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 19th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research report on Friday, July 29th. Bank of America Corp. downgraded shares of Seres Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 1st. Finally, Canaccord Genuity reissued a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a research report on Monday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $34.43.
The company has a 50 day moving average price of $26.48 and a 200-day moving average price of $27.18. The company’s market capitalization is $365.16 million.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.02. The business had revenue of $2.71 million for the quarter, compared to analyst estimates of $1.25 million. On average, analysts expect that Seres Therapeutics Inc. will post ($1.86) earnings per share for the current year.
In other Seres Therapeutics news, insider Michele Trucksis sold 4,156 shares of the company’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $35.18, for a total value of $146,208.08. Following the transaction, the insider now directly owns 4,156 shares in the company, valued at approximately $146,208.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John G. Aunins sold 9,390 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $27.23, for a total transaction of $255,689.70. Following the completion of the sale, the executive vice president now directly owns 32,655 shares of the company’s stock, valued at approximately $889,195.65. The disclosure for this sale can be found here.
Several large investors have made changes to their positions in the company. Morgan Stanley boosted its stake in shares of Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock valued at $1,185,000 after buying an additional 23,381 shares during the last quarter. BlackRock Advisors LLC boosted its stake in shares of Seres Therapeutics by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 340,871 shares of the company’s stock valued at $11,962,000 after buying an additional 2,443 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock valued at $13,999,000 after buying an additional 7,259 shares during the last quarter.
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.